Abeona Breaks Ground on Gene Therapy Manufacturing Facility in Cleveland

Rare Daily Staff

Gene therapy developer Abeona Therapeutics said it broke ground on The Elisa Linton Center for Rare Disease Therapies, a commercial gene therapy manufacturing facility in Cleveland.

The company said the facility will have the capacity to produce advanced gene and cell therapies to treat serious and debilitating rare diseases.

The facility was named for Elisa Linton, who was born with Sanfilippo syndrome, a rare terminal disease. “The memory of Elisa and courage of her family continue to be a great inspiration to all members of the rare disease community,” said Timothy Miller, CEO of Abeona.

The facility will be used to produce ABO-101 and ABO-102, experimental gene therapies currently in development at Abeona for the treatment of patients with Sanfilippo syndrome, and EB-101, an investigational autologous cell therapy for the treatment of recessive dystrophic epidermolysis bullosa, a rare and devastating skin disorder.

The center will also house Abeona’s expanded viral-vector lab, which will develop and produce unique and proprietary vectors used for the delivery of gene therapies. The 6,000 square foot center will be built-out and validated over the next 12 months.

October 4, 2017